Author

Laurent Peyrin-Biroulet

3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 1: Diagnosis and Medical Management
3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 1: Diagnosis and Medical Management

Laurent Peyrin-Biroulet  et al.

SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB AND VEDOLIZUMAB IN IBD IN CLINICAL REMISSION IS ASSOCIATED WITH A LOWER RATE OF DRUG DISCONTINUATION, DRUG OPTIMIZATION, AND REVERSE-SWITCH: AN INTERNATIONAL MULTICENTER STUDY
SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB AND VEDOLIZUMAB IN IBD IN CLINICAL REMISSION IS ASSOCIATED WITH A LOWER RATE OF DRUG DISCONTINUATION, DRUG OPTIMIZATION, AND REVERSE-SWITCH: AN INTERNATIONAL MULTICENTER STUDY

Laurent Peyrin-Biroulet  et al.

EFFICACY AND SAFETY OF ADVANCED ORAL THERAPIES FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS
EFFICACY AND SAFETY OF ADVANCED ORAL THERAPIES FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS

Laurent Peyrin-Biroulet  et al.

EARLY FECAL CALPROTECTIN LEVELS PREDICT POSTOPERATIVE RECURRENCE OF CROHN’S DISEASE: DATA FROM THE REPREVIO TRIAL
EARLY FECAL CALPROTECTIN LEVELS PREDICT POSTOPERATIVE RECURRENCE OF CROHN’S DISEASE: DATA FROM THE REPREVIO TRIAL

Laurent Peyrin-Biroulet  et al.

ASSOCIATION OF ULCERATIVE COLITIS BOWEL URGENCY IMPROVEMENT WITH CLINICAL RESPONSE AND REMISSION
ASSOCIATION OF ULCERATIVE COLITIS BOWEL URGENCY IMPROVEMENT WITH CLINICAL RESPONSE AND REMISSION

Laurent Peyrin-Biroulet  et al.

USE OF FAECAL CALPROTECTIN AS A PROGNOSTIC MARKER OF RESPONSE TO TREATMENT WITH FILGOTINIB: POST HOC ANALYSIS FROM THE SELECTION STUDY
USE OF FAECAL CALPROTECTIN AS A PROGNOSTIC MARKER OF RESPONSE TO TREATMENT WITH FILGOTINIB: POST HOC ANALYSIS FROM THE SELECTION STUDY

Laurent Peyrin-Biroulet  et al.

EFFICACY AND SAFETY OUTCOMES UP TO ~4 YEARS OF TREATMENT WITH FILGOTINIB 200 MG AMONG PATIENTS WITH ULCERATIVE COLITIS: RESULTS FROM THE SELECTIONLTE STUDY
EFFICACY AND SAFETY OUTCOMES UP TO ~4 YEARS OF TREATMENT WITH FILGOTINIB 200 MG AMONG PATIENTS WITH ULCERATIVE COLITIS: RESULTS FROM THE SELECTIONLTE STUDY

Laurent Peyrin-Biroulet  et al.

CANCER INCIDENCE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND A PRIOR NON-DIGESTIVE MALIGNANCY ACCORDING TO THE IMMUNOMODULATORY THERAPY: A MULTICENTER COHORT STUDY
CANCER INCIDENCE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND A PRIOR NON-DIGESTIVE MALIGNANCY ACCORDING TO THE IMMUNOMODULATORY THERAPY: A MULTICENTER COHORT STUDY

Laurent Peyrin-Biroulet  et al.

EFFICACY OF MIRIKIZUMAB IN RESOLVING ACTIVE HISTOLOGIC INFLAMMATION IN ULCERATIVE COLITIS IN LUCENT-1 INDUCTION AND LUCENT-2 MAINTENANCE TRIALS
EFFICACY OF MIRIKIZUMAB IN RESOLVING ACTIVE HISTOLOGIC INFLAMMATION IN ULCERATIVE COLITIS IN LUCENT-1 INDUCTION AND LUCENT-2 MAINTENANCE TRIALS

Laurent Peyrin-Biroulet  et al.

WHICH SECOND-LINE BIOLOGIC AFTER ANTI-TNF FAILURE DURING CROHN'S DISEASE: USTEKINUMAB OR VEDOLIZUMAB, A MULTICENTRE RETROSPECTIVE STUDY
WHICH SECOND-LINE BIOLOGIC AFTER ANTI-TNF FAILURE DURING CROHN'S DISEASE: USTEKINUMAB OR VEDOLIZUMAB, A MULTICENTRE RETROSPECTIVE STUDY

Laurent Peyrin-Biroulet  et al.

SYMPTOMS AND LABORATORY VALUES AS PROXIES FOR ENDOSCOPIC AND HISTOLOGIC CLINICAL ENDPOINTS IN ULCERATIVE COLITIS: A MEDIATION ANALYSIS BASED ON UPADACITINIB PHASE 3 INDUCTION TRIALS
SYMPTOMS AND LABORATORY VALUES AS PROXIES FOR ENDOSCOPIC AND HISTOLOGIC CLINICAL ENDPOINTS IN ULCERATIVE COLITIS: A MEDIATION ANALYSIS BASED ON UPADACITINIB PHASE 3 INDUCTION TRIALS

Laurent Peyrin-Biroulet  et al.

USTEKINUMAB IMPROVES HEALTH-RELATED QUALITY-OF-LIFE IN PATIENTS WITH MODERATE-TO-SEVERE CROHN´S DISEASE: RESULTS FROM A WEEK 16 INTERIM ANALYSIS OF THE STARDUST TRIAL
USTEKINUMAB IMPROVES HEALTH-RELATED QUALITY-OF-LIFE IN PATIENTS WITH MODERATE-TO-SEVERE CROHN´S DISEASE: RESULTS FROM A WEEK 16 INTERIM ANALYSIS OF THE STARDUST TRIAL

Laurent Peyrin-Biroulet  et al.

PHARMACOKINETICS AND IMMUNOGENICITY OF MAINTENANCE THERAPY WITH USTEKINUMAB: 2-YEAR RESULTS FROM THE UNIFI LONG-TERM EXTENSION STUDY
PHARMACOKINETICS AND IMMUNOGENICITY OF MAINTENANCE THERAPY WITH USTEKINUMAB: 2-YEAR RESULTS FROM THE UNIFI LONG-TERM EXTENSION STUDY

Laurent Peyrin-Biroulet  et al.

HEPATIC IMPACT OF ETRASIMOD FOR TREATMENT OF MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: AN INTEGRATED SAFETY SUMMARY FROM THE ETRASIMOD ULCERATIVE COLITIS CLINICAL PROGRAMME
HEPATIC IMPACT OF ETRASIMOD FOR TREATMENT OF MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: AN INTEGRATED SAFETY SUMMARY FROM THE ETRASIMOD ULCERATIVE COLITIS CLINICAL PROGRAMME

Laurent Peyrin-Biroulet  et al.

USTEKINUMAB IS MORE EFFECTIVE THAN AZATHIOPRINE TO PREVENT ENDOSCOPIC POSTOPERATIVE RECURRENCE IN CROHN´S DISEASE
USTEKINUMAB IS MORE EFFECTIVE THAN AZATHIOPRINE TO PREVENT ENDOSCOPIC POSTOPERATIVE RECURRENCE IN CROHN´S DISEASE

Laurent Peyrin-Biroulet  et al.

IGA VASCULITIS ASSOCIATED WITH INFLAMMATORY BOWEL DISEASES: A MULTICENTER STUDY OF THE GETAID AND GFEV
IGA VASCULITIS ASSOCIATED WITH INFLAMMATORY BOWEL DISEASES: A MULTICENTER STUDY OF THE GETAID AND GFEV

Laurent Peyrin-Biroulet  et al.

EFFICACY AND SAFETY OF USTEKINUMAB FOR ULCERATIVE COLITIS THROUGH 4 YEARS: FINAL RESULTS FROM THE UNIFI LONG-TERM EXTENSION
EFFICACY AND SAFETY OF USTEKINUMAB FOR ULCERATIVE COLITIS THROUGH 4 YEARS: FINAL RESULTS FROM THE UNIFI LONG-TERM EXTENSION

Laurent Peyrin-Biroulet  et al.

EFFICACY OF USTEKINUMAB FOR ULCERATIVE COLITIS IN PATIENTS THROUGH 3 YEARS: UNIFI LONG-TERM EXTENSION
EFFICACY OF USTEKINUMAB FOR ULCERATIVE COLITIS IN PATIENTS THROUGH 3 YEARS: UNIFI LONG-TERM EXTENSION

Laurent Peyrin-Biroulet  et al.

ENDOSCOPIC SUBMUCOSAL DISSECTION IN INFLAMMATORY BOWEL DISEASE PATIENTS FOR VISIBLE DYSPLASIA: A FRENCH RETROSPECTIVE MULTICENTRIC STUDY
ENDOSCOPIC SUBMUCOSAL DISSECTION IN INFLAMMATORY BOWEL DISEASE PATIENTS FOR VISIBLE DYSPLASIA: A FRENCH RETROSPECTIVE MULTICENTRIC STUDY

Laurent Peyrin-Biroulet  et al.

PHARMACOKINETICS, IMMUNOGENICITY, AND EXPOSURE-RESPONSE RELATIONSHIP OF USTEKINUMAB IN PATIENTS WITH CROHN'S DISEASE: RESULTS FROM THE WEEK 16 INTERIM ANALYSIS OF THE STARDUST STUDY
PHARMACOKINETICS, IMMUNOGENICITY, AND EXPOSURE-RESPONSE RELATIONSHIP OF USTEKINUMAB IN PATIENTS WITH CROHN'S DISEASE: RESULTS FROM THE WEEK 16 INTERIM ANALYSIS OF THE STARDUST STUDY

Laurent Peyrin-Biroulet  et al.

Item 81 - 100 / 115
1 2 3 4
5
6